Global Retirement Partners LLC Purchases New Stake in Stryker Corporation $SYK

Global Retirement Partners LLC acquired a new position in Stryker Corporation (NYSE:SYK) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 10,532 shares of the medical technology company’s stock, valued at approximately $3,316,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC boosted its stake in shares of Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after purchasing an additional 609 shares during the last quarter. Schnieders Capital Management LLC. bought a new stake in shares of Stryker during the second quarter worth approximately $205,000. Marshall Wace LLP lifted its holdings in Stryker by 107.9% in the second quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock valued at $2,255,000 after buying an additional 77,831 shares during the period. Nebula Research & Development LLC acquired a new position in Stryker in the second quarter valued at approximately $219,000. Finally, HUB Investment Partners LLC bought a new position in Stryker in the second quarter valued at approximately $253,000. 77.09% of the stock is owned by institutional investors.

Stryker Stock Down 0.1%

Shares of NYSE SYK opened at $338.80 on Monday. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $396.86. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The stock has a market cap of $129.95 billion, a P/E ratio of 35.11, a P/E/G ratio of 2.16 and a beta of 0.76. The firm has a 50 day moving average price of $324.61 and a 200 day moving average price of $333.40.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping the consensus estimate of $3.49 by $0.20. The company had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period last year, the business posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Analysts expect that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.0%. Stryker’s payout ratio is currently 36.48%.

Wall Street Analyst Weigh In

A number of analysts have commented on SYK shares. Citigroup reaffirmed a “buy” rating on shares of Stryker in a report on Thursday. Royal Bank Of Canada reduced their price target on Stryker from $435.00 to $420.00 and set an “outperform” rating on the stock in a research report on Friday, July 31st. Truist Financial lifted their price objective on Stryker from $330.00 to $340.00 and gave the stock a “hold” rating in a research note on Friday, July 31st. JPMorgan Chase & Co. decreased their price objective on Stryker from $400.00 to $350.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Stryker in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $386.28.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of the business’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the transaction, the director directly owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. The trade was a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the sale, the vice president directly owned 10,582 shares in the company, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.60% of the stock is currently owned by insiders.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.